SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

palazestrant

OLMA·Olema Oncology
NEUTRAL
Drug Impact Rating8/10
Trial phase
Phase 3
Time to market
If the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.
Why 8/10
The next hard, dated catalyst is the SABCS 2026 presentation in December 2026 (combination data), but the truly pivotal binary event is the Phase 3 OPERA-01 topline readout expected in Q1 2027. Palazestrant is Olema's only clinical-stage asset and drives essentially the entire company valuation, making the OPERA-01 readout a make-or-break event. However, since the readout is 3-5 months away (not within 6 months from today), the impactScore is capped at 8 per the rubric.
Actionable Insight NEUTRAL

The next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.

Price Chart

Loading chart...

Executive Summary

Palazestrant (OP-1250) is Olema Pharmaceuticals' lead and only clinical-stage drug candidate, an oral small molecule with a dual CERAN/SERD mechanism targeting ER+/HER2- metastatic breast cancer. It is currently being evaluated in two Phase 3 trials: OPERA-01 (monotherapy in 2nd/3rd-line) and OPERA-02 (first-line combination with ribociclib). The pivotal OPERA-01 topline readout is expected in Q1 2027, making this the defining binary catalyst for the company. The stock trades at ~$7.27, down roughly 80% from its 52-week high, with a mean analyst price target of $36.50 (Strong Buy consensus) and very high short interest of ~19.6% of outstanding shares. Near-term catalysts include combination data presentations at SABCS 2026 in December.

How It Works

Palazestrant is an oral (pill) small molecule that attacks estrogen-receptor-positive (ER+) breast cancer through two mechanisms: it completely blocks the estrogen receptor from being activated (complete antagonism, the CERAN mechanism) and it also degrades the receptor protein itself (SERD mechanism). This dual action is designed to more thoroughly shut down estrogen-driven cancer growth than drugs that only do one or the other. It is taken daily as a pill.

Trial Status

Two pivotal Phase 3 trials are underway: OPERA-01 (monotherapy in 2nd/3rd-line ER+/HER2- metastatic breast cancer) completed enrollment in mid-2026 with top-line data expected Q1 2027; OPERA-02 (first-line combination with ribociclib) is actively enrolling. Earlier Phase 1b/2 combination data with ribociclib has been presented at ESMO and SABCS conferences showing encouraging preliminary activity.

The Two-Sided Case

▲ Bull Case5
Palazestrant has a differentiated dual mechanism as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), which the company believes may offer superior efficacy versus pure SERDs like elacestrant or giredestrant.
The analyst consensus is Strong Buy (16 Buy/Strong Buy vs 2 Hold, 0 Sell) with a mean price target of $36.50, implying roughly 400% upside from the current ~$7.27 price, reflecting high expectations for the OPERA-01 readout.
Roche's positive Phase 3 data for giredestrant (Lidera/EvERA trials) in 2025 validated the oral SERD class and sent OLMA shares up over 100% in a single day, showing the stock's extreme sensitivity to positive class-level signals.
Enrollment in the pivotal Phase 3 OPERA-01 trial is completed, and the company continues strong enrollment in OPERA-02 (first-line combination), suggesting investigators see promise in the drug.
Major institutional investors like Point72, Morgan Stanley, and Vanguard increased positions significantly in Q2 2026, and the Q3 2026 data shows continued accumulation by several funds.
▼ Bear Case5
Palazestrant is a single-product pipeline for a clinical-stage company with no approved drugs and a net loss of $73.6M in Q3 2026 alone, meaning significant shareholder dilution risk if the OPERA-01 readout is delayed or negative.
The oral SERD/CERAN class is increasingly crowded: Roche's giredestrant has positive Phase 3 data, AstraZeneca's camizestrant is advancing, and elacestrant (Orserdu) is already approved. Palazestrant needs to show clear differentiation to capture meaningful market share.
Short interest is very high at ~19.6% of outstanding shares (11.9 days to cover as of Oct 30, 2026), reflecting substantial bearish conviction that the drug may fail or underwhelm.
Several large institutional holders exited in Q2 2026, including RA Capital Management ($38.7M position), Jennison Associates ($27.2M), and Polar Capital ($23.9M), suggesting skepticism from sophisticated healthcare investors.
The stock has fallen from a 52-week high of $36.26 to ~$7.27, a roughly 80% decline, indicating the market has already priced in significant doubt about the drug's prospects.

Upcoming Catalysts

  • SABCS 2026 (December 2026): Presentation of combination data for palazestrant + ribociclib and OP-3136 preclinical/clinical data
  • OPERA-01 Phase 3 topline data readout: Expected Q1 2027 (the primary binary catalyst for the stock)
  • OPERA-02 Phase 3 enrollment completion and potential interim updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Olema Oncology PRESS-RELEASE OLMA ·Originating report

Sources · 10

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 streetinsider.com4 seekingalpha.com5 msn.com6 seekingalpha.com7 markets.financialcontent.com8 marketscreener.com9 ascopubs.org10 biospace.com